At a glance
- Originator Sanofi-Synthelabo
- Class
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 23 Jun 2003 Discontinued - Preclinical for Chronic obstructive pulmonary disease in France (unspecified route)
- 17 Sep 2002 Preclinical data from the XVIIth Int Med Chem Symp have been added to the pharmacodynamics section
- 12 Sep 2000 Preclinical development for Chronic obstructive pulmonary disease in France (Unknown route)